PEBC: What You Should Know: SGLT2 Inhibitors

Examples: empagliflozin, canagliflozin, dapagliflozin, ertugliflozin

Benefits: reduced progression to heart failure, renal disease, cardiovascular event (but loses effectiveness in severe renal impairment)

Mechanism: Inhibits the sodium-glucose transporter, preventing reuptake of glucose and leading to glucose urination.

Dose: once daily, most are taken before breakfast to ensure full benefit of action (urination)

Adverse Effects:

-frequent urination

-mild weight loss

-dizziness (slight decrease in blood pressure)

-genital and urinary tract infections (fungal too)

-increased risk of diabetic ketoacidosis

-slight risk of hyperkalemia

Drug Interactions:

loop diuretics such as furosemide (and other diuretics) - increased hypotension risk